Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy

Scripps Health

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: Food Allergy Peanut

Treatments: Biological: Peanut allergen

Study type: Interventional

Funder types: Other

Identifiers

NCT04200989

IRB-19-7380

Details and patient eligibility

About

Use of three intralymphatic injections of peanut allergen one month apart to induce tolerance to peanut in peanut allergic people.

Full description

Eligible subject undergo a baseline blinded oral peanut challenge. Then the peanut ILIT as described above. Pretreatment with antihistamines, leukotriene modifier and albuterol before each treatment.

Following the three ILIT peanut injections a repeat blinded oral peanut challenge is performed.

Blood is drawn at each of the 5 study visits for a variety of tests trying to elucidate the mechanism(s) of the induction of tolerance to peanut.

Sex: All

Ages: 15 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

History of peanut allergy Positive prick skin tests or invitro IgE to peanut Positive blinded oral peanut challenge.

Exclusion criteria

History of

• life threatening anaphylaxis to peanut Uncontrolled asthma

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Treatment

Experimental group

Description:

Peanut ILIT

Treatment:

Biological: Peanut allergen